REQUEST A DEMO
Total
USD $0.00
Search more companies

Hemomont D.O.O. (Montenegro)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Hemomont D.O.O. Podgorica Profile Updated: September 12, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

In November 1994, Serbia's leading drug maker Hemofarm launched its Montenegrin operations entering a joint venture with the Montenegrin Health Fund and the Montenegro Bank to create Hemomont, the first plant producing simple medical solutions in the republic. Hemomont has a factory for sterile production of liquid forms and a factory for solid dosage forms production. Besides the infusion solutions in glass bottles, the company's product portfolio features aseptic ophthalmic preparations in the form of eye drops in plastic and glass bottles, tablets and capsules.

Headquarters
Ul. 8. Marta 55a
Podgorica; Podgorica; Postal Code: 81000

Contact Details: Purchase the Hemomont D.O.O. report to view the information.

Website: http://www.hemofarm.com

Basic Information
Total Employees:
Purchase the Hemomont D.O.O. report to view the information.
Outstanding Shares:
Purchase the Hemomont D.O.O. report to view the information.
Incorporation Date:
Key Executives
Purchase this report to view the information.
Executive Director
Purchase this report to view the information.
Representative
Ownership Details
Purchase this report to view the information.
71.02%
Purchase this report to view the information.
19.35%
Purchase this report to view the information.
9.63%
Company Performance
Financial values in the chart are available after Hemomont D.O.O. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency EUR. Absolute financial data is included in the purchased report.
Net sales revenue
23.37%
Total operating revenue
22.95%
Operating profit (EBIT)
29.88%
EBITDA
20.79%
Net Profit (Loss) for the Period
48.3%
Total assets
6.51%
Total equity
9.75%
Operating Profit Margin (ROS)
0.28%
Net Profit Margin
0.78%
Return on Equity (ROE)
2.31%
Debt to Equity Ratio
0.59%
Quick Ratio
0.25%
Cash Ratio
0.05%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?